CORRECTION - Citadel Securities Initiates Coverage on Dendreon (DNDN) to Neutral; PROVENGE Market Overestimated
Tweet Send to a FriendGet Alerts DNDN Hot Sheet
Price: $3.99 +0.76%
Rating Summary:
5 Buy, 15 Hold, 12 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 28 | New: 13
Rating Summary:
5 Buy, 15 Hold, 12 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 28 | New: 13
Trade DNDN Now!
Citadel Securities initiates coverage on Dendreon (NASDAQ: DNDN) to Neutral with a price target of $10.00.
Citadel analyst says, "In our view, revenue expectations for Dendreon's PROVENGE drug are widely overestimated. We acknowledge that PROVENGE is a new form of treatment for metastatic castrate-resistant prostate cancer and therefore may garner some attention, but we believe revenue and market estimates are too high. We believe the actual addressable market for PROVENGE is roughly 17,000–35,000 patients, much lower than the 100,000 patients cited by the company. We estimate peak sales of $580MM in 2015 vs. consensus of $1.1B, and 2011 revenues of $169MM vs. consensus of $233MM."
For more ratings news on Dendreon click here and for the rating history of Dendreon click here.
Shares of Dendreon closed at $12.56 yesterday, with a 52 week range of $11.34-$43.96.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Citadel analyst says, "In our view, revenue expectations for Dendreon's PROVENGE drug are widely overestimated. We acknowledge that PROVENGE is a new form of treatment for metastatic castrate-resistant prostate cancer and therefore may garner some attention, but we believe revenue and market estimates are too high. We believe the actual addressable market for PROVENGE is roughly 17,000–35,000 patients, much lower than the 100,000 patients cited by the company. We estimate peak sales of $580MM in 2015 vs. consensus of $1.1B, and 2011 revenues of $169MM vs. consensus of $233MM."
For more ratings news on Dendreon click here and for the rating history of Dendreon click here.
Shares of Dendreon closed at $12.56 yesterday, with a 52 week range of $11.34-$43.96.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Cantor Fitzgerald Upgrades Cubist Pharmaceuticals (CBST) to Hold
- UPDATE: JPMorgan Cuts SodaStream (SODA) to Neutral, 'Stock No Longer Cheap'
- The ExOne Company (XONE) Metal Opportunity to Keep Stock Going - FBR
Create E-mail Alert Related Categories
Upgrades
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
